作者: Lin Shen , Zhi-hao Lu
DOI: 10.3760/CMA.J.ISSN.1671-0274.2012.02.002
关键词:
摘要: Perioperative chemotherapy for gastric cancer has made steady progress with the application of chemotherapeutic agents and conduct relevant clinical trials.However,palliative only marginal progress, median survival remains between 8-10 months,An emerging understanding tumor biology,cellular molecular mechanisms revealed novel targets in therapy,such as trastuzumab,bevacizumab,cetuximab,etc.There are still some problems practice due to high heterogeneity including optimization perioperative regimen,determination right strategy personalize or target therapy advanced cancer. In order practically achieve individualized therapy,multicenter,prospective,randomized trials according specific matters should be performed China.A deeper biological characteristics cancer,and more translational medicine research multi-disciplinary team collaboration carded out personalized medicine. Key words: Stomach neoplasms; Chemotherapy; Target therapy; Personalized